Table 3 Costing change-point analysis of products
Product and standard cost in 2023 USD | Cost to be prioritized over prior product in 2023 USD | Cost to be prioritized behind next product in 2023 USD |
|---|---|---|
IFA, 3.11 per supplemented pregnancy | US $2 — to be prioritized over MMN at the lowest budget sizes | N/A |
MMN, 4.75 per supplemented pregnancy | N/A — no prior product | US $15 |
SAM treatment, 57.32 per treated child | US $19 | US $178 |
Targeted MAM treatment, 40.69 per treated child | US $15 | N/A — will never be less cost effective than universal MAM due to model constraints |
Universal MAM treatment, 40.69 per treated child | N/A — will never be more cost effective than targeted MAM due to model constraints | US $45 |
SQ-LNS, 48.98 for 12-month supplementation | US $44 | US $54 |
Targeted BEP, 55.18 per supplemented pregnancy | US $55 | N/A — no later product |